Eli Lilly and Company (LLY · NYSE)

LLY · MARKET VIEW

Market view · as of Aug 24, 2026

Revenue (TTM)
$79.67B
+47.7% YoY
Gross margin
83.4%
EPS (latest q)
$8.38
vs $6.01 est · beat
52-wk position
95.8%
-1.9% vs 52w high · +5.1% 1mo

Price (last ~year)

Eli Lilly and Company (LLY) maintains a $1.12 trillion market capitalization, supported by 47.7% year-over-year revenue growth and four consecutive quarterly earnings beats. The pharmaceutical manufacturer reported $22.97 billion in revenue for the quarter ending June 30, 2026, alongside an 83.4% gross margin and 54.2% operating margin. Shares are trading at $1255.40, reflecting a 16.1% increase over the last three months and a P/E ratio of 42.2.

Valuation

Market cap
$1.12T
P/E
42.2
PEG
1.579
P/B
33.03
P/S
14.05
EV/EBITDA
27.93
Beta
0.506
Analyst target
$1315.04

Quality & returns

Gross margin
83.4%
Operating margin
54.2%
Profit margin
33.5%
ROE
102.3%
ROA
20.4%

Price movement

Last
$1255.40
1-month
+5.1%
3-month
+16.1%
RSI (14)
70
vs SMA200
+19.6%
52-wk position
95.8% -1.9% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$22.97B$8.98B$7.09B$9.25B
2026-03-31$19.80B$8.85B$7.40B$9.69B
2025-12-31$19.29B$8.78B$6.64B$8.39B
2025-09-30$17.60B$8.39B$5.58B$7.88B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots